[Prophylaxis and therapy of fungal infections in oncology].
The observation of a considerable incidence of fungal infections in oncology patients has promoted a large number of studies both on prophylaxis and treatment in this patient group. Trials using triazoles, especially fluconazole, have shown effect in preventing fungal infections. In neutropenic patients, their role in therapy still remains less clear. Amphotericin B is the drug of choice for most life-threatening infections. With this drug, efforts concentrate upon the amelioration of side effects by sodium loading, administration in lipid emulsions or liposomes. The use of AMB as low-dose systemic prophylaxis or by inhalation needs further study.
Schuler
U
U
Medizinische Klinik I, Universitätsklinikum, Dresden, FR Germany.
Mölle
M
M
Ehninger
G
G
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications*; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D014230:Triazoles; D000666:Amphotericin B; D015725:Fluconazole
Prophylaxe und Therapie von pilzinfektionen in der Onkologie.